Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZ-801 in Early Alzheimer's Disease and APOE4/4 Genotype
NCT04770220Phase 3Completed
- Sponsor
- Alzheon, Inc.
- Start
- May 2021
- Primary completion
- May 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of valiltramiprosate in Alzheimer's disease (AD), sponsored by Alzheon, Inc.. Started May 2021; status: completed.
02
Drugs
valiltramiprosate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04770220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770220.